Resistance to molecular therapies for hepatocellular carcinoma
And Future Challenges for Cancer Stem Cell Research in HCCReferences; Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma; Introduction; Lessons from Second-Line Clinical Trials in HCC; Preclinical and Translational Data on Mechanisms of Sorafenib...
Saved in:
| Other Authors: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
2017.
|
| Series: | Resistance to targeted anti-cancer therapeutics ;
v. 13. |
| Subjects: | |
| ISBN: | 9783319561974 9783319561981 9783319858500 9783319561967 |
| Physical Description: | 1 online resource |
Cover
Table of contents
| LEADER | 05064cam a2200493Mi 4500 | ||
|---|---|---|---|
| 001 | 97431 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20240914110553.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 170721s2017 sz o 001 0 eng d | ||
| 040 | |a YDX |b eng |e pn |c YDX |d N$T |d EBLCP |d GW5XE |d N$T |d UAB |d YDX |d OCLCO |d ESU |d AZU |d UPM |d OCLCF |d COO |d OCLCQ |d MERER |d VT2 |d OCLCQ |d IOG |d JG0 |d OCLCO |d OCLCA |d SNK |d U3W |d OCLCO |d CAUOI |d OCLCO |d KSU |d OCLCO |d WYU |d OCLCO |d OCLCA |d UKAHL |d OCLCQ |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ | ||
| 020 | |a 9783319561974 |q (electronic bk.) | ||
| 020 | |a 9783319561981 |q (print) | ||
| 020 | |a 9783319858500 |q (print) | ||
| 020 | |z 9783319561967 | ||
| 024 | 7 | |a 10.1007/978-3-319-56197-4 |2 doi | |
| 035 | |a (OCoLC)994368683 |z (OCoLC)994145793 |z (OCoLC)995020726 |z (OCoLC)1002346028 |z (OCoLC)1005764014 |z (OCoLC)1011934952 |z (OCoLC)1048179027 |z (OCoLC)1066472851 |z (OCoLC)1103262833 | ||
| 245 | 0 | 0 | |a Resistance to molecular therapies for hepatocellular carcinoma / |c Augusto Villanueva, editor. |
| 260 | |a Cham : |b Springer, |c 2017. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 490 | 1 | |a Resistance to targeted anti-cancer therapeutics, |x 2196-5501 ; |v v. 13 | |
| 505 | 0 | |a Dedication; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope ; About the Editor; Preface; Contents; Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma; Introduction; Spectrum of Heterogeneity in Hepatocellular Carcinoma: Impact on Drug Resistance; Intra-Tumor Heterogeneity in Hepatocellular Carcinoma; Approaches to Evaluate Heterogeneity; Conclusion; References; Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma; Immunological Landscape of the Liver; Immunological Environment in Liver Cancer. | |
| 505 | 8 | |a Modulation of the Immunological Response in Patients with Liver Cancer Cytokine-Based Strategies; Oncolytic Virotherapy; Tumor Vaccines; Adoptive Cell Therapy; Checkpoint Inhibitors; References; Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance; Introduction; Liver Fibrosis and Hepatic Stellate Cells (HSCs); Inflammation and Immune Cells; Tumor Associated Macrophages; Myeloid Derived Suppressor Cells; Natural Killer Cells; Regulatory T Cells; Effector T Cells; Angiogenesis and Hypoxia; Concluding Remarks; References. | |
| 505 | 8 | |a Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance Introduction; The Cellular Origin of Hepatic Cancer Stem Cells; The Importance of the Hepatic Microenvironment for Induction of a Cancer Stem Cell Phenotype; Identification of Cancer Stem Cells and Clinical Relevance of Cancer Stem Cell Markers in Liver Cancer; Cancer Stem Cell Regulation, Targeting and Mechanisms of Chemoresistance; Targeting Stemness-Related Signaling Pathways; Targeting Drug Resistance: ABCG2 Transporter; Differentiation Therapy; Epigenetic Modifications and CSC Therapy. | |
| 505 | 8 | |a Assessment of Response to Molecular Targeted Therapies Assessment of Response to Immuno-Therapies; Conclusions; References; Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma; Introduction; Adverse Events in HCC Patients Receiving Sorafenib; Radiological Responses and the Role of Post-progression Survival; Cirrhosis Complications as Confounders of Sorafenib Resistance; The Role of Alpha-Fetoprotein (AFP) Evolution as a Marker of Resistance; Other Potential Confounding Factors When Defining Sorafenib Resistance; References. | |
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a And Future Challenges for Cancer Stem Cell Research in HCCReferences; Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma; Introduction; Lessons from Second-Line Clinical Trials in HCC; Preclinical and Translational Data on Mechanisms of Sorafenib Resistance; Future Perspectives; References; Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma; Introduction; mRECIST Assessment at Baseline; mRECIST Evaluation of Tumor Response; Assessment of Response to Loco-Regional Therapies. | ||
| 500 | |a Includes index. | ||
| 590 | |a SpringerLink |b Springer Complete eBooks | ||
| 650 | 0 | |a Liver |x Cancer |x Chemotherapy. | |
| 650 | 0 | |a Drug resistance in cancer cells. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Villanueva, Augusto. | |
| 776 | 0 | 8 | |i Print version: |t Resistance to molecular therapies for hepatocellular carcinoma. |d Cham : Springer, 2017 |z 9783319561967 |z 3319561960 |w (OCoLC)975368226 |
| 830 | 0 | |a Resistance to targeted anti-cancer therapeutics ; |v v. 13. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-56197-4 |y Plný text |
| 992 | |c NTK-SpringerBLS | ||
| 999 | |c 97431 |d 97431 | ||
| 993 | |x NEPOSILAT |y EIZ | ||
Save to List
Cite this
Export Record
Email this